Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL286 Target Snapshot

Renin · SINGLE PROTEIN · Homo sapiens

3,417Compounds
539Assays
3Approved Drugs
4,902.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Renin shows approved-linked disease relevance led by hypertension. 4 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P00797. Start with hypertension, then reuse UniProt P00797 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hypertension, then reuse UniProt P00797 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
hypertension

Renin shows approved-linked disease relevance led by hypertension. 4 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with hypertension because it currently carries approved-linked support. Linked drugs include ALISKIREN FUMARATE, SITOKIREN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Renin as ChEMBL target CHEMBL286, mapped to UniProt P00797. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Renin
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL286
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P00797
Renin
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Renin is the right protein anchor across sources, using UniProt P00797 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hypertension is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRenin
UniProt AccessionP00797
Component TypeProtein
Sequence Length406 aa

Renin

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Renin, mapped to UniProt P00797. Sequence length is 406 aa.

Mapped IDP00797
Review nameRenin
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Renin shows approved-linked disease relevance led by hypertension. 4 more disease programs remain visible in the same review block.

Approved-linked Approved
hypertension
2 linked drugs · 2 direct · 2 efficacy
Linked drugALISKIREN FUMARATE
Linked drugSITOKIREN
Approved-linked Approved
stroke
1 linked drug · 1 direct · 1 efficacy
Linked drugALISKIREN FUMARATE
Late clinical Phase III
essential hypertension
1 linked drug · 1 direct · 1 efficacy
Linked drugSITOKIREN
Clinical signal Phase II
diabetic nephropathy
1 linked drug · 1 direct · 1 efficacy
Linked drugSITOKIREN
Clinical signal Phase II
ulcerative colitis
1 linked drug · 1 direct · 1 efficacy
Linked drugSITOKIREN
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with hypertension because it currently carries approved-linked support. Linked drugs include ALISKIREN FUMARATE, SITOKIREN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehypertension
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

3
Approved
1
Phase III
12
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC504,701.0
KI183.0
KD18.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1761533 11.0 IC50 0.01 Preclinical
CHEMBL1761535 11.0 IC50 0.01 Preclinical
CHEMBL1761673 11.0 IC50 0.01 Preclinical
CHEMBL1761519 10.7 IC50 0.02 Preclinical
CHEMBL1761532 10.7 IC50 0.02 Preclinical
CHEMBL1761534 10.7 IC50 0.02 Preclinical
CHEMBL1796073 10.7 IC50 0.02 Preclinical
CHEMBL1761522 10.66 IC50 0.022 Preclinical
CHEMBL31601 10.6 IC50 0.025 Clinical
CHEMBL3144404 10.59 Ki 0.026 Preclinical
Distribution

pChEMBL Value Distribution

178
5.0
196
5.5
371
6.0
453
6.5
538
7.0
594
7.5
649
8.0
642
8.5
507
9.0
191
9.5
pChEMBL
Approved Drugs

Approved Drugs

ALISKIREN
CHEMBL1639
Approved 2007
ALISKIREN FUMARATE
CHEMBL3545059
Approved 2007
CAPTOPRIL
CHEMBL1560
Approved 1981
Assay Landscape

Assay Landscape

539
Total Assays
3,467
Tested Compounds
3
Assay Types
Binding — 470 assays, 3,467 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 300 2,313 7.7
cell-free format 142 1,004 7.6
tissue-based format 13 66 7.7
cell-based format 10 72 7.7
assay format 5 12 6.5
Functional — 68 assays, 78 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 59 0
cell-free format 5 40 7.9
assay format 3 28 8.1
tissue-based format 1 10 8.1
ADME — 1 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine